Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes

Autoimmune diseases are often associated with autoantibodies that abnormally target self-antigens (autoantigens). An intuitive therapeutic strategy for diseases caused by aAbs is to design decoys, or soluble molecules that target the antigen combining site of these aAbs, thereby blocking binding of...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 812649
Main Authors Cardozo, Timothy, Cardozo, Lila, Boutjdir, Mohamed
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 28.01.2022
Subjects
Antibodies, Monoclonal - chemistry
Antibodies, Monoclonal - immunology
Autoantibodies - immunology
autoantibody
autoantigen
Autoantigens - analysis
Autoantigens - immunology
autoimmune
Autoimmune Diseases - diagnosis
Autoimmune Diseases - immunology
Cardiomyopathies
decoy
Humans
Immunoassay
Immunology
long QT
Phenotype
therapeutics
therapeutics
autoantibody
autoimmune
decoy
autoantigen
long QT
Online AccessGet full text

Cover

More Information
Summary:Autoimmune diseases are often associated with autoantibodies that abnormally target self-antigens (autoantigens). An intuitive therapeutic strategy for diseases caused by aAbs is to design decoys, or soluble molecules that target the antigen combining site of these aAbs, thereby blocking binding of aAb to self-antigen and subsequent tissue damage. Here, we review the known decoy molecules of these types, discuss newer technological opportunities afforded by monoclonal antibody and structural biology advances, and discuss the challenges to this approach. Recent opportunities relevant to this approach for cardiac phenotypes, specifically Ro-associated long QT syndrome, are discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Ivan Dario Mascanfroni, Q32 Bio, United States
This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology
Reviewed by: Joanne Reed, Westmead Institute for Medical Research, Australia
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.812649